试验注册状态与不孕干预随机对照试验中大型治疗效应报告的关系:一项元流行病学研究
该元流行病学研究纳入2012至2023年发表的1369项不孕随机对照试验,其中19.8%为前瞻性注册、29.6%为回顾性注册、50.6%未注册。与前瞻性注册试验相比,回顾性注册(aRR=0.77;95%CI 0.49-1.20)或未注册试验(aRR=1.07;95%CI 0.71-1.66)报告大型治疗效应的可能性无统计学显著差异。结论不支持系统评价中一律排除未注册或回顾性注册的RCT。
要点
- 不孕RCT中仅19.8%为前瞻性注册,50.6%未注册。
- 回顾性注册或未注册与报告大型治疗效应无显著关联。
- 不支持系统评价中一律排除未注册或回顾性注册的RCT。
核心结论
- 未注册或回顾性注册的不孕RCT并未表现出更倾向于报告大型治疗效应。
- 研究结果不支持将未注册或回顾性注册的RCT一律排除在系统评价之外。
研究设计与样本
- 元流行病学研究,系统检索Embase、Medline和CENTRAL,纳入2012至2023年发表的不孕RCT。
- 共纳入1369项RCT,其中前瞻性注册19.8%、回顾性注册29.6%、未注册50.6%。
- 主要结局为报告大型治疗效应,定义为妊娠或活产具有统计学显著性的相对风险低于0.80或高于1.25。
- 采用Poisson回归(对数链接)分析注册状态与大型治疗效应报告的关联,以前瞻性注册为参照组,并调整潜在混杂因素。
主要发现
- 与前瞻性注册试验相比,回顾性注册试验报告大型治疗效应的校正相对风险(aRR)为0.77(95%CI 0.49-1.20)。
- 与前瞻性注册试验相比,未注册试验报告大型治疗效应的aRR为1.07(95%CI 0.71-1.66)。
- 在2018年后发表的试验中,上述结果保持一致。
- 在2018年前发表的试验中,回顾性注册与报告大型治疗效应的可能性显著降低相关(aRR=0.40;95%CI 0.21-0.75)。
临床怎么用
- 系统评价者在纳入不孕RCT时,不应仅因试验未注册或回顾性注册而一律排除。
- 可结合试验发表时间等因素综合评估注册状态对效应量报告的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While prospective registration is a key measure to prevent selective reporting, excluding unregistered or retrospectively registered trials would greatly reduce the statistical power of systematic reviews. OBJECTIVE: We aimed to explore the association between trial registration status and the reporting of large treatment effects on pregnancy or live birth. EVIDENCE REVIEW: This is a meta-epidemiologic study of infertility randomized controlled trials (RCTs) published between 2012 and 2023, identified through systematic searches of Embase, Medline, and CENTRAL. Eligible RCTs involved infertile couples and reported outcomes on biochemical, clinical, ongoing pregnancy, or live birth. Conference abstracts, secondary analyses of RCTs, or trials with unclear registration timing were excluded. The primary outcome was reporting of large treatment effects, defined as a statistically significant relative risk for pregnancy or live birth below 0.80 or above 1.25. The association between trial registration status and reporting of large treatment effects was analyzed using a Poisson regression with a log link, adjusted for potential confounders, with prospective registration as the reference group. FINDINGS: Among 1,369 infertility RCTs, 19.8% were prospectively registered, 29.6% were retrospectively registered, and 50.6% were unregistered. Compared with prospectively registered trials, there was no statistically significant difference in the likelihood of reporting large treatment effects among retrospectively registered trials (adjusted relative risk [aRR] = 0.77; 95% confidence interval [CI]: 0.49-1.20) or unregistered trials (aRR = 1.07; 95% CI, 0.71-1.66). These findings remained consistent in analyses restricted to trials published after 2018. In trials published before 2018, retrospective registration was associated with a significantly lower likelihood of reporting large treatment effects (aRR = 0.40; 95% CI, 0.21-0.75). CONCLUSION AND RELEVANCE: The reporting of large treatment effects has not been shown to be greater in unregistered or retrospectively registered infertility trials. Our findings do not support the blanket exclusion of all unregistered or retrospectively registered RCTs from systematic reviews.
引用
- Feng Q, Li W, Crispin J, et al. Association between trial registration and reporting large treatment effects in randomized controlled trials of infertility interventions: a meta-epidemiological study. Fertil Steril. 2026. PMID: 41921890. doi:10.1016/j.fertnstert.2026.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。